GT BIOPHARMA, INC. Gain (Loss) on Extinguishment of Debt
GT BIOPHARMA, INC. (GTBP) reported Gain (Loss) on Extinguishment of Debt of $200.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-14
- GT BIOPHARMA, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was -$798.00K.
- GT BIOPHARMA, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was $798.00K.
- GT BIOPHARMA, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was -$798.00K.
- GT BIOPHARMA, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-03-31 was $998.00K.
- GT BIOPHARMA, INC. gain (loss) on extinguishment of debt for fiscal 2025 was $200.00K.
- GT BIOPHARMA, INC. gain (loss) on extinguishment of debt for fiscal 2023 was $547.00K, a 1664.52% increase from fiscal 2022.
- GT BIOPHARMA, INC. gain (loss) on extinguishment of debt for fiscal 2022 was $31.00K.
- GT BIOPHARMA, INC. gain (loss) on extinguishment of debt for fiscal 2017 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 6 month as first filed | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | -$798.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-06 | -$798.00K derived: sum of 3 quarters · filed 2026-08-14 | $200.00K 10-K · filed 2026-03-02 | |
| 2025-09-30 | $798.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2026-03-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $998.00K 10-Q/A · filed 2026-03-06 | ||
| 2025-06-30 | -$798.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $200.00K 10-Q · filed 2026-08-14 | $998.00K 10-Q · filed 2025-08-14 | ||
| 2025-03-31 | $998.00K 10-Q · filed 2026-05-15 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $0.00 derived: sum of 2 quarters · filed 2025-02-21 | $14.00K derived: sum of 3 quarters · filed 2025-02-21 | $547.00K 10-K · filed 2025-02-21 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $14.00K derived: sum of 2 quarters · filed 2024-11-14 | $547.00K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $14.00K 10-Q · filed 2024-08-14 | $547.00K 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | $533.00K 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | $31.00K 10-K · filed 2023-03-30 | ||||
| 2017-12-31 | $0.00 10-K · filed 2018-03-01 | ||||
| 2016-12-31 | $0.00 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |